The recent interesting article by Ohye et al1 addressed the continuing problem of nonprescribed and occult medication use. I applaud the scientific dedication of the 2 lead authors who took it upon themselves to ingest the implicated tablets, which have been analyzed to contain portions of tetraiodothyronine (T4) and triiodothyronine (T3). Most would have been convinced without the need to take this extra step, which is unnecessary for 2 reasons. The first is that data on the pharmacokinetic of T3 and T4 are well established.2 The 34 μg to 45 μg of T4 would have few biological effects owing to the binding of T4 to circulating proteins. As the half-life of T4 is 7 to 10 days, a good 4 to 6 weeks of consistent T4 ingestion would need to occur to ensure a therapeutic level. The elevated T3 level is consistent with its short half-life, and the dose approximates that used therapeutically. Thus, its transient use is reflected biologically in a mild reduction in thyroid-stimulating hormone level. The second reason is the effect of self-testing, which may unmask other unheralded medical conditions, particularly that which is specific to my and the authors’ heritage. This is best highlighted in the following clinical vignette.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.